🏢 Company

Biogen

American pharmaceutical company

📊 Rating

7 news mentions · 👍 0 likes · 👎 0 dislikes

📌 Topics

Stock Downgrade (3)
Pharma Acquisition (2)
Pharmaceuticals (2)
Pharmaceutical R&D (1)
Corporate Finance (1)
Pharmaceutical Merger (1)
Rare Diseases (1)
Pharmaceutical Acquisition (1)
Finance (1)
Mergers & Acquisitions (1)

🏷️ Keywords

Biogen (7) · acquisition (6) · Apellis (4) · stock rating (4) · pharmaceuticals (4) · downgrade (2) · Apellis Pharmaceuticals (2) · $5.6 billion (2) · R&D expenses (1) · $34 million charge (1) · research and development (1) · financial impact (1) · pharmaceutical (1) · innovation investment (1) · Roth/MKM (1) · rare diseases (1) · complement system (1) · neuroscience (1) · immunology (1) · Cantor Fitzgerald (1)

📖 Key Information

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis.